Background/aims: Pneumonia is a common type of infection in maintenance hemodialysis (MHD) patients, while the treatment and prevention progress still keep limited. N-terminal-pro-brain natriuretic peptide (NT-proBNP) is an important marker in reflecting cardiac failure which also is a risk factor for pneumonia. This study aimed to determine the possible predictive value of NT-proBNP for pneumonia in MHD patients.
Methods: In this prospective study, the basic information of 276 MHD patients was collected in Fudan university Zhongshan hospital, followed up for 1 year. The primary endpoint was the first pneumonia event during follow-up. The value of NT-proBNP in patients with pneumonia and without pneumonia was analyzed, to elucidate the predictive value of the NT-proBNP in hemodialysis patients with pneumonia.
Results: Two hundred and seventy-six patients were finally enrolled in this prospective study, including 170 men. The mean age was 59.7 ± 14.0 years old. The average duration of hemodialysis is 56 (30-82.8) months. Enrolled patients were followed up for 1 year. During follow-up, 38 patients got pneumonia. After adjustment for other confounding factors, age (hazard ratio [HR] 1.031, 95% CI 1.003-1.060, p = 0.028), log NT-proBNP (HR 2.512, 95% CI 1.124-5.612, p = 0.025), history of smoking (HR 6.326, 95% CI 2.505-15.974, p < 0.001), β2-microglobin (HR 1.042, 95% CI 1.007-1.079, p = 0.019), and history of cerebrovascular disease (HR 2.303, 95% CI 1.107-4.719, p = 0.026) were independent predictors of pneumonia. Receiver operating characteristic curves of log NT-proBNP to predict 1 year pneumonia cases, log NT-proBNP had an area under the curve of 0.647 (95% CI [0.564-0.729], p < 0.01).
Conclusions: NT-proBNP is a predictive factor of pneumonia in hemodialysis patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000504524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimated total amyloid burden from 18F-florbetaben PET predicts all-cause mortality in light-chain cardiac amyloidosis.
Eur Heart J Cardiovasc Imaging
December 2024
Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Background And Aims: The positron emission tomography (PET) tracer 18F-florbetaben is a promising diagnostic tool for light-chain cardiac amyloidosis (AL-CA). A greater cardiac uptake might signal more amyloid burden and a worse outcome. We aimed to assess the prognostic significance of 18F-florbetaben uptake in AL-CA.
View Article and Find Full Text PDFPrevalence of Transthyretin Amyloid Cardiomyopathy Among Acute Heart Failure Patients with Hypertrophy Across the Left Ventricular Ejection Fraction Spectrum.
J Clin Med
November 2024
University Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Transthyretin amyloid (ATTR) cardiomyopathy mimics left ventricular hypertrophy (LVH) and has been identified as a specific cause of heart failure (HF). The aim of this study was to assess the prevalence of ATTR among patients presenting to the Emergency Department (ED) with acute HF (AHF) and LVH and explore their clinical characteristics and outcomes. Of 127 AHF patients with LVH, 95 completed the diagnostic protocol, which included monoclonal paraprotein testing and technetium-99 m pyrophosphate scintigraphy.
View Article and Find Full Text PDFPost-discharge changes in nutritional status predict prognosis in patients with acute decompensated HFpEF from the PURSUIT-HFpEF Registry.
Heart Vessels
December 2024
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Article Synopsis
- Undernutrition has a negative impact on patients with heart failure and preserved ejection fraction (HFpEF), affecting their long-term prognosis after discharge.
- A study categorized 547 HFpEF patients based on their nutritional status at discharge and one year later, identifying those who normalized or worsened in their nutritional scores.
- The findings revealed that worsening nutritional scores increased the risk of all-cause mortality or readmission, while improving scores were linked to better outcomes, with certain predictors identified for changes in nutritional status.
A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.
Am J Cardiovasc Drugs
December 2024
Office of Human Research, Memorial Healthcare System, Hollywood, FL, 33021, USA.
Article Synopsis
- Sodium-glucose cotransporter 2 inhibitors (SGLT2is) show promise as a treatment for heart failure (HF) in adults with adult congenital heart disease (ACHD), but more research is needed.
- A systematic review and meta-analysis of eight studies with 287 patients indicated that SGLT2is improved functional class and reduced NT-proBNP levels, along with a decrease in systolic blood pressure.
- The medications were generally well tolerated, with minor side effects reported, but there were no serious complications like hypoglycemia or ketoacidosis, highlighting the need for further large-scale studies to verify these findings.
Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure.
Heart
November 2024
Department of Cardiology, University of Groningen, Groningen, Netherlands
Background: We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.
Methods: BMP10 levels were quantified in 2085 chronic HF patients from the European BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort and in 1487 patients from the Scottish validation cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!